
stra**tec**••



STRATEC 9M/2023 FINANCIAL RESULTS

Birkenfeld, 2023-10-27

PEOPLE | INNOVATION | PARTNERSHIP

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

strateco

I. 9M/2023 HIGHLIGHTS

- 2. FINANCIAL REVIEW
- 3. OUTLOOK
- 4. Q&A
- 5. APPENDIX

- Sales -9.1% at constant-currency to €187.7 million
 - Sales performance still adversely affected by excess molecular diagnostics capacities built up during pandemic
 - Market demand does not yet break through due to destocking effects following global supply crisis
 - Stockholdings at customers expected to return to normal levels at the beginning/in the middle of 2024
- Significant intra-year improvement in profitability in Q3/2023 with adjusted EBIT margin of 14.8%
 - Substantial progress within initiated earnings improvement program (current run rate ahead of schedule)
- Financial guidance for 2023: sales guidance slightly adjusted and margin target confirmed
- Well-stocked development pipeline and significant expansion of two major development cooperations

strateco

I. 9M/2023 HIGHLIGHTS

2. FINANCIAL REVIEW

- 3. OUTLOOK
- 4. Q&A
- 5. APPENDIX

FINANCIALS AT A GLANCE¹


€ 000s	9M/2023	9M/2022	Change	Q3/2023	Q3/2022	Change
Sales	187,680	207,654	-9.6%	62,674	70,461	-11.1%
Adjusted EBITDA	27,267	48,095	-43.3%	13,370	20,254	-34.0%
Adjusted EBITDA margin (%)	14.5	23.2	-870 bps	21.3	28.7	-740 bps
Adjusted EBIT	16,222	38,067	-57.4%	9,257	16,889	-45.2%
Adjusted EBIT margin (%)	8.6	18.3	-970 bps	14.8	24.0	-920 bps
Adjusted consolidated net income	9,742	29,549	-67.0%	5,682	12,870	-55.9%
Adjusted basic earnings per share (in €)	0.80	2.44	-67.2%	0.47	1.06	-55.7%
Basic earnings per share IFRS (in €)	0.62	2.04	-69.6%	0.42	1.00	-58.0%

Adj. = adjusted / bps = basis points

¹ For comparison purposes, adjusted figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (advisory expenses and restructuring costs relating to M&A activities and one-off personnel expenses). In the previous year, the figures were additionally adjusted to exclude a provision for expected back payments of tax (including interest payments).

FINANCIAL REVIEW

SALES 9M/2023




As of September 30

Sales in 9M/2023 -9.6% to € 187.7 million \rightarrow -9.1% at constant currency

(-) Pandemic related overcapacities within MDx market and still elevated inventory levels at customers

- (-) Low utilization levels within the installed base limits growth with service parts
- (+) Slight growth with development and service sales versus tough prior year base of comparison
- (+) Growing contributions from newly launched systems

ADJUSTED EBIT AND EBIT MARGIN 9M/2023



9M/2023 adjusted EBIT down by 57.4% yoy to € 16.2 million, margin at 8.6%

stratec••

- (-) Negative economies of scale
- (-) Product mix effects
- (+) Implemented price adjustments
- (+) Targeted measures in areas of personnel and development

Significant improvement in Q3/2023 with adjusted EBIT margin of 14.8%

As of September 30

FINANCIAL REVIEW

stra**tec**••

CASH FLOW AND NET DEBT

€ 000s	9M/2023	9M/2022	Change
Cash flow – operating activities	10,709	22,285	-51.9%
Cash flow – investment activities	-45,666	-16,921	n/a
Cash flow – financing activities	26,634	-16,938	n/a
Free cash flow	-34,957	5,364	n/a

€ 000s	9M/2023	FY/2022	Change
Cash	14,315	22,668	-36.8 %
Equity ratio (%)	51.0	56.6	-560 bps
Net debt	131,803	76,619	+72 %

- Operating cash flow burdened by lower operating profitability and still materially inflated inventory levels
- Cash flow from investment activities includes
 € 27.7 million outflow for Natech Plastics acquisition
- Investment ratio¹ at 7.5% of sales versus 5.8% in 9M/2022 → in-line with full year target corridor of 6.0% to 8.0%
- Net debt / EBITDA² ~3x

¹ Total investments in intangible and tangible assets in % of sales ² Based on EBITDA forecast for 2023

- I. 9M/2023 HIGHLIGHTS
- 2. FINANCIAL REVIEW
- 3. OUTLOOK
- 4. Q&A
- 5. APPENDIX



stratec••

EARNINGS IMPROVEMENT PROGRAM*

Focus area	Earnings impact 2024 (pre-tax)	Status
 Personnel measures Temporary and partial hiring freeze Reallocation of resources Reduction of personnel related consultancy costs, etc. 	+4.0 to +5.0 million €	 Hiring freeze implemented since March 2023 On track to achieve positive earnings impact of around € 4.0 million already in 2023
Focused price adjustment strategies	+5.0 to +8.0 million €	 Price increases for major products have become effective as of 1 July 2023
 Non-personnel cost reductions and others Procurement optimizations Product portfolio optimizations Others 	+1.0 to +2.0 million €	 Extended program to optimize procurement structures and processes initiated First positive effects from logistical measures on the back of improved market environment
TOTAL	+10.0 to +15.0 million €	

*Compared with the original company budget





UPDATED GUIDANCE FOR FISCAL YEAR 2023

- Adjustment of sales outlook 2023: Sales expected to fall slightly short on a constant-currency basis compared to previous year (previously: sales to remain stable or grow slightly)
 - Ongoing and pandemic-related period of subdued developments in the molecular diagnostics instrumentation solutions market
- Adjusted EBIT margin of around 10.0% to 12.0% (2022: 16.4%) confirmed
 - Implemented price increases and further progress in the execution of earnings improvement program
- Investments in tangible and intangible assets combined of around 6.0% to 8.0% of sales *confirmed*





QUESTIONS & ANSWERS

APPENDIX

stra**tec**••

ADJUSTMENTS 9M/2023

EBIT

€ 000s	9M/2023	9M/2022
Adjusted EBIT	16,222	38,067
Adjustments:		
PPA amortization Other ¹	-1,713 -1,217	-2,627 0
EBIT	13,292	35,440

¹ Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

Consolidated net income

€ 000s	9M/2023	9M/2022
Adjusted consolidated net income	9,742	25,549
Adjusted earnings per share in € (basic)	0.80	2.44
Adjustments:		
PPA amortization	-1,713	-2,627
Other ¹	-1,217	0
Taxes on income	714	-2,020
Interest expenses	0	-183
Consolidated net income	7,526	24,719
Earnings per share in € (basic)	0.62	2.04

¹ Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

CONTACT

STRATEC SE Gewerbestr. 37 75217 Birkenfeld Germany

Phone +49 7082 7916-0 Fax +49 7082 7916-999 www.stratec.com

CONTACT

Jan Keppeler, CFA Head of Investor Relations, Sustainability & Corporate Communications

Phone +49 7082 7916-6515 j.keppeler@stratec.com



THANK YOU FOR YOUR ATTENTION